soul trial oral semaglutide cardiovascular outcomes results 2025 nejm 2024 Presented at ACC.25: Among participants SOUL: Oral Semaglutide Bests Usual – 📌 Most viewed this week

Coskun and Urva (2022, pharmacological description) describe the engineering: modified sequence derived from native GIP, Aib2 and Aib13 substitutions resisting DPP-4, and a C20 diacid fatty-acyl chain grafted to a lysine via a gamma-glutamate linker to extend half-life to approximately 6 days

[2] In March 2026, the FDA sent warning letters to 30 telehealth companies over misleading marketing of compounded GLP-1 products

Liraglutide treatment reduced interleukin-6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy

A decision could come later this year

Billing: Immediately, the providers screen shows PA Request: Submitted with a reference ID